A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 20 Aug 2019 Biomarkers information updated
- 21 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.